<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796938</url>
  </required_header>
  <id_info>
    <org_study_id>SP0641</org_study_id>
    <nct_id>NCT01796938</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects</brief_title>
  <official_title>Open, Non-randomized, Sequential Group Comparison to Investigate the Pharmacokinetics, Safety, and Tolerability of 100 mg SPM 927 in Male and Female Subjects With Renal Impairment Including Subjects Requiring Dialysis Compared With Male and Female Healthy Subjects Following Single-dose Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB BIOSCIENCES GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the Pharmacokinetics (PK) of oral administered Lacosamide in renal impaired&#xD;
      subjects and healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Lacosamide plasma concentration time curve from 0 to the last quantifiable data point (AUC(0-tz))</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measured maximal concentration (Cmax) of Lacosamide</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Lacosamide plasma concentration-time curve from 0 to the last quantifiable data point (AUC (0-tz)), normalized by body weight</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measured maximal concentration (Cmax, norm) of Lacosamide normalized by body weight</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of observed maximum (tmax) of Lacosamide concentration</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of observed maximum (tmax) of Lacosamide metabolite (SPM12809) concentration</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of Lacosamide</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of Lacosamide metabolite (SPM12809)</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance (CL/f) of Lacosamide from plasma</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the lacosamide metabolite (SPM12809) plasma concentration-time curve from 0 to the last quantifiable data point (AUC(0-tz))</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Lacosamide excreted in urine from 0 to defined time point (Ae(0-48)) (t=48 hours)</measure>
    <time_frame>Day 1 to Day 3 of study</time_frame>
    <description>Urine sampling predose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Lacosamide metabolite (SPM12809) excreted in urine from 0 to defined time point (Ae(0-48)) (t=48 hours)</measure>
    <time_frame>Day 1 to Day 3 of study</time_frame>
    <description>Urine sampling predose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured maximal concentration (Cmax) of Lacosamide metabolite (SPM12809)</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Lacosamide metabolite (SPM12809) plasma concentration time curve from 0 to the last quantifiable data point (AUC(0-tz)), normalized by body weight</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured maximal Lacosamide metabolite (SPM12809) concentration (Cmax,norm), normalized by body weight</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of Lacosamide in urine</measure>
    <time_frame>Day 1 to Day 3 of study</time_frame>
    <description>Urine sampling predose, 0-4, 4-8, 8-12, 12-24, 24-36, and 36-48 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lacosamide concentration in dialysis inlet line (Cin)</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lacosamide metabolite (SPM12809) concentration in dialysis inlet line (Cin)</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lacosamide concentration in dialysis outlet line (Cout)</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lacosamide metabolite (SPM12809) concentration in dialysis outlet line (Cout)</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extraction rate (E) of Lacosamide</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extraction rate (E) of Lacosamide metabolite (SPM12809)</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis clearance (CLdial) of Lacosamide</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis clearance (CLdial) of Lacosamide metabolite (SPM12809)</measure>
    <time_frame>From 4 hours up to 6 hours postdose</time_frame>
    <description>Dialysis samples collected 4 hours and 6 hours after administration (1.5 hours and 3.5 hours after start of dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate constant of Lacosamide elimination</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate constant of Lacosamide metabolite (SPM12809) elimination</measure>
    <time_frame>Day 1 to Day 5 of study</time_frame>
    <description>Blood sampling at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, and 96 hours after single dose administration; &gt; 24 hours excluded for group 5</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1: Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg Lacosamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Subjects with mild renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg Lacosamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Subjects with moderate renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg Lacosamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Subjects with severe renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg Lacosamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Subjects with end stage renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg Lacosamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide tablet</intervention_name>
    <description>Single dose of 100 mg Lacosamide tablet</description>
    <arm_group_label>Group 1: Healthy subjects</arm_group_label>
    <arm_group_label>Group 2: Subjects with mild renal insufficiency</arm_group_label>
    <arm_group_label>Group 3: Subjects with moderate renal insufficiency</arm_group_label>
    <arm_group_label>Group 4: Subjects with severe renal insufficiency</arm_group_label>
    <arm_group_label>Group 5: Subjects with end stage renal insufficiency</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject was informed and given ample time and opportunity to think about his/her&#xD;
             participation and had given his/her written informed consent&#xD;
&#xD;
          -  Subject was willing and able to comply with all trial requirements&#xD;
&#xD;
          -  Subject was a male or female Caucasian, between 18 and 70 years of age (inclusive)&#xD;
&#xD;
          -  If female, subject was of non-childbearing potential (post-menopausal or&#xD;
             hysterectomized) or was using medically adequate contraception&#xD;
&#xD;
          -  If female of childbearing potential, subject had a negative pregnancy test&#xD;
&#xD;
          -  Subject had a Body Mass Index (BMI) between 20 and 34 kg/m2 (inclusive)&#xD;
&#xD;
          -  Subject was healthy without clinically relevant cardiovascular, renal,&#xD;
             gastrointestinal, hepatic, metabolic, endocrine, neurological, or psychiatric&#xD;
             abnormalities detected during Eligibility Assessment (EA)&#xD;
&#xD;
        Subjects with renal impairment also had to fulfill the following inclusion criteria:&#xD;
&#xD;
          -  Subject had no clinically relevant cardiovascular or endocrine findings during EA&#xD;
&#xD;
          -  Subject had a renal impairment. The subjects were assigned to 1 of the following&#xD;
             treatment groups according to Creatinine Clearance (CLCr) values determined 2 to 7&#xD;
             days prior to dosing:&#xD;
&#xD;
          -  Group 2: 80 mL/min &gt; CLCr ≥ 50 mL/min (subjects with mild renal impairment)&#xD;
&#xD;
          -  Group 3: 50 mL/min &gt; CLCr ≥ 30 mL/min (subjects with moderate renal impairment)&#xD;
&#xD;
          -  Group 4: CLCr &lt; 30 mL/min (subjects with severe renal impairment, not on dialysis&#xD;
             between 2 weeks before EA and end of the trial)&#xD;
&#xD;
        Inclusion criteria for Group 5:&#xD;
&#xD;
          -  Subject was informed and given ample time and opportunity to think about his/her&#xD;
             participation and had given his/her written informed consent&#xD;
&#xD;
          -  Subject was willing and able to comply with all trial requirements&#xD;
&#xD;
          -  Subject was a male or female Caucasian, between 18 and 70 years of age (inclusive)&#xD;
&#xD;
          -  If female, subject was of non-childbearing potential (post-menopausal or&#xD;
             hysterectomized) or was using medically adequate contraception&#xD;
&#xD;
          -  If female of childbearing potential, subject had a negative pregnancy test&#xD;
&#xD;
          -  Subject had a BMI between 20 and 34 kg/m2 (inclusive)&#xD;
&#xD;
          -  Subject had no clinically relevant cardiovascular or endocrine findings during EA&#xD;
&#xD;
          -  Subject had an endstage renal disease (CLCr &lt; 15 mL/min, determined approximately 2 to&#xD;
             7 days before first dosing) treated with extracorporal hemodialysis for at least 4&#xD;
             months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  Subject had previously participated in this trial&#xD;
&#xD;
          -  Subject had participated in another trial of an investigational product within the&#xD;
             last 3 months or was currently participating in another trial of an investigational&#xD;
             product&#xD;
&#xD;
          -  Subject had donated blood or had a comparable blood loss (&gt; 500 mL) within the last 3&#xD;
             months prior to EA&#xD;
&#xD;
          -  Subject smoked more than 5 cigarettes per day or had done so within the 6 months prior&#xD;
             to commencement of this trial&#xD;
&#xD;
          -  Subject had a history of chronic alcohol or drug abuse within the last 6 months prior&#xD;
             to commencement of this trial&#xD;
&#xD;
          -  Subject consumed more than 40 g of alcohol/day (amount corresponds to 1 L beer/day or&#xD;
             0.5 L wine/day or 120 mL liquor/day)&#xD;
&#xD;
          -  Subject had positive tests for alcohol (urine or breath test) or drugs (urine test)&#xD;
&#xD;
          -  Subject had clinically relevant changes in the electrocardiogram (ECG), such as&#xD;
             second- or third-degree atrioventricular (AV) block, prolongation of the QRS complex&#xD;
             over 120 ms or of the corrected QT (QTc) interval &gt; 430 ms (male subjects) or &gt; 450 ms&#xD;
             (female subjects)&#xD;
&#xD;
          -  Subject had a history or present condition of clinically relevant respiratory or&#xD;
             cardiovascular disorders, eg, cardiac insufficiency, coronary heart disease,&#xD;
             hypertension, arrhythmia, tachyarrhythmia, or status after myocardial infarction&#xD;
&#xD;
          -  Subject had a history or present condition of psychic abnormality, psychiatric or&#xD;
             neurologic illness, or autonomic neuropathy that, in the opinion of the Investigator,&#xD;
             could have jeopardized or would have compromised the subject's ability to participate&#xD;
             in the trial&#xD;
&#xD;
          -  Subject had a history or present condition of seizure disorder&#xD;
&#xD;
          -  Subject had a history or present condition of malignancy&#xD;
&#xD;
          -  Subject had a history or present condition of renal disorders (albuminuria, chronic&#xD;
             infections) or renal impairment&#xD;
&#xD;
          -  Subject had a history or present condition of Diabetes Mellitus or thyroid&#xD;
             dysfunction, especially Hyperthyreosis, or other endocrine disorders&#xD;
&#xD;
          -  Subject had a clinically relevant allergy&#xD;
&#xD;
          -  Subject had a known or suspected drug hypersensitivity, in particular to the trial&#xD;
             medication&#xD;
&#xD;
          -  Subject was taking any concomitant medication currently or within 2 weeks prior to the&#xD;
             first day of dosing (with the exception of oral contraceptives and Paracetamol&#xD;
             [maximum allowed dose: 1000 mg/dose], which were allowed up to 48 hours prior to&#xD;
             dosing); further exceptions could be made if the Investigator and the sponsor jointly&#xD;
             considered the medication as acceptable&#xD;
&#xD;
          -  Subject was tested positive for human immunodeficiency virus 1/2 antibodies&#xD;
             (HIV-1/2-Ab), hepatitis B surface antigen (HBs-Ag), or hepatitis C virus antibody&#xD;
             (HCV-Ab)&#xD;
&#xD;
          -  Subject had any clinically relevant abnormality in the physical examination or in&#xD;
             vital sign measurements (systolic blood pressure &gt; 150 mmHg or &lt; 100 mmHg, diastolic&#xD;
             blood pressure &gt; 95 mmHg or &lt; 60 mmHg, pulse rate &gt; 100 beats per minute (bpm) or &lt; 50&#xD;
             bpm)&#xD;
&#xD;
          -  Subject had a clinically relevant deviation from the norm in the clinical chemistry,&#xD;
             hematology, or urinalysis evaluations&#xD;
&#xD;
        Exclusion criteria for Groups 2-4:&#xD;
&#xD;
          -  Exclusion criteria 1 to 12 for healthy subjects also applied to subjects with renal&#xD;
             impairment&#xD;
&#xD;
          -  Subject had a clinically relevant allergy&#xD;
&#xD;
          -  Subject had a known or suspected drug hypersensitivity, in particular to the trial&#xD;
             medication&#xD;
&#xD;
          -  Subject was taking any concomitant medication currently or within 2 weeks prior to&#xD;
             dosing that could have interfered with the investigational product&#xD;
&#xD;
          -  Subject was tested positive for HIV-1/2-Ab, HBs-Ag, or HCV-Ab&#xD;
&#xD;
          -  Subject had any clinically relevant abnormality in the physical examination or in&#xD;
             vital sign measurements (systolic blood pressure &gt; 180 mmHg or &lt; 100 mmHg, diastolic&#xD;
             blood pressure &gt; 110 mmHg, pulse rate &gt; 100 bpm or &lt; 60 bpm)&#xD;
&#xD;
          -  Subject had a clinically relevant deviation from the norm in the clinical chemistry,&#xD;
             hematology or urinalysis evaluations other than expected for a subject with renal&#xD;
             impairment, eg, hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
        Exclusion criteria for Group 5:&#xD;
&#xD;
          -  Exclusion criteria 1 to 12 for healthy subjects also applied to subjects in Group 5&#xD;
&#xD;
          -  Subject had a clinically relevant allergy&#xD;
&#xD;
          -  Subject had a known or suspected drug hypersensitivity, in particular to the trial&#xD;
             medication&#xD;
&#xD;
          -  Subject was tested positive for HIV-1/2-Ab, HBs-Ag, or HCV-Ab&#xD;
&#xD;
          -  Subject was taking any concomitant medication that might interfere with the&#xD;
             investigational product currently or within 2 weeks prior to dosing&#xD;
&#xD;
          -  Subject had any clinically relevant abnormality in the physical examination or in&#xD;
             vital sign measurements (systolic blood pressure &gt; 200 mmHg [predialysis value] or &lt;&#xD;
             100 mmHg, diastolic blood pressure &gt; 110 mmHg, pulse rate &gt; 100 bpm or &lt; 60 bpm)&#xD;
&#xD;
          -  Subject had a clinically relevant deviation from the norm in the clinical chemistry,&#xD;
             hematology, or urinalysis evaluations other than expected for a patient with renal&#xD;
             impairment, eg, hemoglobin &lt; 8.0 g/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2</name>
      <address>
        <city>Rendsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Vimpat</keyword>
  <keyword>Single Dose</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Renal Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

